The global clinical trials market is estimated at over $80–90 billion in 2024 and is projected to surpass $120 billion by 2030, driven by rising R&D investments, the growth of biologics and precision medicine, and increasing trial complexity. The Asia-Pacific region is emerging as the fastest-growing market, as sponsors shift studies to geographies offering faster patient recruitment, cost efficiencies, and diverse populations.

Speakers

The growing focus on biosimilars and biologics marks a strategic shift from volume-driven generics to high-value innovation-led therapies. The global biosimilars market is witnessing exponential expansion, valued at nearly $39.6 billion in 2025 and projected to exceed $150 billion by 2033.